Lynnor Stevenson

Dr. Stevenson has served as a board member of Sedia since 2010. She was formerly Chair and Chief Executive Officer of DesignMedix, a pharmaceutical company focused on globally-important infectious diseases including malaria. Dr. Stevenson is a successful entrepreneur with forty years experience in the formation and growth of bioscience companies. She was a Managing Partner of Alta Biomedical Group, a consulting firm with projects in the commercialization of innovative technology. She has been a member of the early-stage management teams for ten start-up companies, six of which are now public. She was founding CEO for 5 years and a director for 18 years of Heska Corporation, an animal health company that develops drugs, vaccines and diagnostics. She was a member of the early-stage teams for Creative BioMolecules (now Curis), AP Pharma, Agen and Univax (now Nabi) and is a founder and director of CytoImage Inc, a company developing single cell cancer diagnosis. In addition to business and R&D experience relating to drugs, vaccines and diagnostics, she has experience in drug development at several companies including the submission of several IND (Investigational New Drug) applications to the FDA. She received B.Sc.Hon. and B.Ed. degrees from Melbourne University and a Ph.D in Biochemistry from Monash University, Australia.